BRIEF—AGC Biologics enters into supply agreement with MacroGenics

Contract Development and Manufacturing Organization (CDMO) AGC Biologics announced today that in late 2017 it entered into a commercial supply agreement with US biotech firm MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.

AGC Biologics has provided comprehensive development and validation services for margetuximab since 2014, and plans to implement a transition to commercial supply services.

Margetuximab is an investigational product that targets the human epidermal growth factor receptor 2, or HER2.

HER2 is expressed by tumor cells in breast, gastroesophageal, bladder and other forms of solid tumor cancers, making it a key marker for biologic therapy.

Margetuximab has an Fc domain, which was engineered to enhance engagement and activation of the immune system.